Intech Investment Management LLC Lowers Stake in Elevance Health, Inc. $ELV

Posted by Brenda Bartman on May 30th, 2026

Intech Investment Management LLC lowered its position in shares of Elevance Health, Inc. (NYSE:ELV – Free Report) by 14.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 27,980 shares of the company’s stock after selling 4,650 shares during the quarter. Intech Investment Management LLC’s holdings in Elevance Health were worth $9,808,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the company. Foundations Investment Advisors LLC lifted its holdings in Elevance Health by 5.9% during the fourth quarter. Foundations Investment Advisors LLC now owns 2,843 shares of the company’s stock valued at $997,000 after purchasing an additional 159 shares in the last quarter. Thoroughbred Financial Services LLC purchased a new position in Elevance Health during the fourth quarter valued at approximately $297,000. Syverson Strege & Co lifted its holdings in Elevance Health by 9.4% during the fourth quarter. Syverson Strege & Co now owns 734 shares of the company’s stock valued at $257,000 after purchasing an additional 63 shares in the last quarter. Unison Asset Management LLC lifted its holdings in Elevance Health by 7.0% during the fourth quarter. Unison Asset Management LLC now owns 27,745 shares of the company’s stock valued at $9,704,000 after purchasing an additional 1,824 shares in the last quarter. Finally, Kestra Investment Management LLC purchased a new position in Elevance Health during the fourth quarter valued at approximately $363,000. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on ELV shares. Mizuho lifted their price target on shares of Elevance Health from $385.00 to $435.00 and gave the company an “outperform” rating in a report on Wednesday, May 20th. Barclays lifted their price objective on shares of Elevance Health from $408.00 to $480.00 and gave the company an “overweight” rating in a research report on Tuesday. Robert W. Baird lifted their price objective on shares of Elevance Health from $317.00 to $331.00 and gave the company a “neutral” rating in a research report on Thursday, April 23rd. Guggenheim lifted their price objective on shares of Elevance Health from $396.00 to $399.00 and gave the company a “buy” rating in a research report on Friday, April 24th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Elevance Health from $397.00 to $411.00 and gave the company an “overweight” rating in a research report on Tuesday, April 28th. Fourteen analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $403.11.

View Our Latest Stock Analysis on Elevance Health

Elevance Health Price Performance

Elevance Health stock opened at $394.40 on Friday. The company has a market cap of $85.65 billion, a price-to-earnings ratio of 16.78, a PEG ratio of 2.22 and a beta of 0.66. The firm’s fifty day moving average is $343.75 and its 200 day moving average is $338.90. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.70. Elevance Health, Inc. has a 52-week low of $273.71 and a 52-week high of $408.00.

Elevance Health (NYSE:ELV – Get Free Report) last released its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. The company had revenue of $49.49 billion for the quarter, compared to the consensus estimate of $48.21 billion. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. Elevance Health’s revenue was up 1.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $11.97 earnings per share. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Sell-side analysts forecast that Elevance Health, Inc. will post 26.94 EPS for the current fiscal year.

Elevance Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be paid a $1.72 dividend. The ex-dividend date of this dividend is Wednesday, June 10th. This represents a $6.88 annualized dividend and a dividend yield of 1.7%. Elevance Health’s dividend payout ratio is currently 29.26%.

About Elevance Health

(Free Report)

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.